- Home
- SBLX vs KALA Comparison
SBLX vs KALA Comparison
Compare SBLX & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLX
- KALA
- Stock Information
- Founded
- SBLX 2017
- KALA 2009
- Country
- SBLX United States
- KALA United States
- Employees
- SBLX N/A
- KALA N/A
- Industry
- SBLX Telecommunications Equipment
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- SBLX Consumer Discretionary
- KALA Health Care
- Exchange
- SBLX Nasdaq
- KALA Nasdaq
- Market Cap
- SBLX 6.0M
- KALA 5.1M
- IPO Year
- SBLX N/A
- KALA 2017
- Fundamental
- Price
- SBLX $2.70
- KALA $0.66
- Analyst Decision
- SBLX
- KALA Buy
- Analyst Count
- SBLX 0
- KALA 3
- Target Price
- SBLX N/A
- KALA $31.50
- AVG Volume (30 Days)
- SBLX 79.8K
- KALA 244.4K
- Earning Date
- SBLX 11-14-2025
- KALA 11-07-2025
- Dividend Yield
- SBLX N/A
- KALA N/A
- EPS Growth
- SBLX N/A
- KALA N/A
- EPS
- SBLX N/A
- KALA N/A
- Revenue
- SBLX N/A
- KALA N/A
- Revenue This Year
- SBLX N/A
- KALA N/A
- Revenue Next Year
- SBLX N/A
- KALA N/A
- P/E Ratio
- SBLX N/A
- KALA N/A
- Revenue Growth
- SBLX N/A
- KALA N/A
- 52 Week Low
- SBLX $2.50
- KALA $0.64
- 52 Week High
- SBLX $15.28
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- SBLX 29.13
- KALA 27.23
- Support Level
- SBLX $3.10
- KALA $0.64
- Resistance Level
- SBLX $3.96
- KALA $0.73
- Average True Range (ATR)
- SBLX 0.47
- KALA 0.06
- MACD
- SBLX -0.07
- KALA 0.32
- Stochastic Oscillator
- SBLX 11.52
- KALA 31.24
About SBLX StableX Technologies Inc. Common Stock
StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.